DOI: 10.6084/m9.figshare.31346845
title: Supplementary data: Treatment burden and healthcare resource utilization in patients with chronic rhinosinusitis with nasal polyps who did or did not undergo functional endoscopic sinus surgery: a US real-world retrospective cohort study

description: <b>These are peer-reviewed supplementary materials for the article</b><b> </b><b>'</b><b>Treatment burden and healthcare resource utilization in patients with chronic rhinosinusitis with nasal polyps who did or did not undergo functional endoscopic sinus surgery: a US real-world retrospective cohort study</b><b>'</b><b> </b><b>published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b><b>Supplementary Table 1: </b>Demographics and comorbidities in the risk-set sampled population of patients with CRSwNP with FESS vs no FESS<b>Supplementary Table 2: </b>Medication use and HCRU during the baseline period in the risk-set sampled population of patients with CRSwNP with FESS vs no FESS<b>Supplementary Table 3: </b>Change in cumulative OCS dose from baseline to follow-up among baseline OCS users* in the PS-matched population of patients with CRSwNP with FESS vs no FESS<b>Supplementary Table 4: </b>All-cause costs during the intervention in the PS-matched population of patients with CRSwNP with FESS vs no FESS<b>Supplementary Table 5: </b>Cumulative OCS dose during follow-up in patients with or without asthma subgroup from the PS-matched population of patients with CRSwNP with FESS vs no FESS<b>Supplementary Table 6: </b>Procedural code list for functional endoscopic sinus surgery (FESS) exposure<b>Supplementary Figure 1: </b>Study design<b>Supplementary Appendix 1: </b>Propensity score (PS) matching<b>Aim:</b> To compare oral corticosteroid (OCS) burden and healthcare resource utilization (HCRU) in patients with chronic rhinosinusitis with nasal polyps undergoing functional endoscopic sinus surgery (FESS; intervention) versus not undergoing FESS. <b>Materials & methods:</b> Retrospective cohort study using US claims data (Optum’s de-identified Clinformatics R ? Data Mart Database; 2011–2021). Groups were propensity score (PS) matched to adjust for confounding. OCS burden (cumulative dose in mg prednisone equivalents) and HCRU were assessed during baseline (365 days pre-index), intervention (days 0–44), and follow-up (days 45–365); costs during intervention and follow-up. <b>Results:</b> Before PS-matching, both groups had substantial comorbidity burden (&gt;50% allergic rhinitis; &gt;25% asthma) and over half of patients had used OCS (65% [FESS] vs 52% [non-FESS]; p &lt; 0.01). After PS-matching (n = 8909 per group), OCS cumulative dose during follow-up was 18% lower among FESS versus non-FESS patients (mean difference: -40 mg per patient [95% CI: -57, -23; p &lt; 0.01]). Similar proportions of patients filled OCS prescriptions during follow-up (35% [FESS], 36% [non-FESS]) and in these patients, OCS burden remained high (mean [SD] cumulative dose 521 [786] vs 612 [906] mg, respectively). Mean total healthcare costs per patient during the intervention period were $28,832 (FESS) and $2537 (non-FESS), but similar during follow-up ($15,659 and $15,926, respectively). HCRU was similar in follow-up, except more FESS patients visited an otolaryngologist (57% vs 32%, p &lt; 0.01). <b>Conclusion:</b> In US clinical practice, OCS burden in patients with chronic rhinosinusitis with nasal polyps was significantly lower but remained substantial following FESS, and HCRU and costs during follow-up were similar to matched patients without FESS.